Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian E-Pharmacy 1mg Raises $70m, Plans Rapid Scale-up

Executive Summary

India’s largest online pharmacy 1mg has raised $70m in its biggest funding round so far, led by Swiss investor Corisol with backing from the World Bank’s finance arm IFC. The company is planning a “rapid scale-up” with the aim of being the top integrated healthcare services provider in the country by 2023.

You may also be interested in...



Indian Chemists’ Strike Seeks Halt To E-Pharmacy Sales

Pharmacies across India staged a one-day shutdown last week to demand a halt to e-pharmacy sales, becoming the latest retail group to oppose a booming online sector that is seen as threatening earnings of traditional bricks-and-mortar stores in the country.

Top US Court Lifts Discovery Stay On Price-Fixing

The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.

FDA Approves First Generic Of Daraprim

Daraprim, which saw its price jacked up by 4,000% by former drug company executive Martin Shkreli, now has a competitor with the US Food and Drug Administration’s approval of the first generic version of the nearly seven-decade-old drug used to treat a life-threatening parasitic infection known as toxoplasmosis.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC125479

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel